¹⁷⁷Lu-PSMA放射性配体疗法治疗转移性阉割耐药前列腺癌。

IF 1.2 Q2 MEDICINE, GENERAL & INTERNAL
Tidsskrift for Den Norske Laegeforening Pub Date : 2024-07-30 Print Date: 2024-08-20 DOI:10.4045/tidsskr.23.0478
Rune Sundset, Hege Sagstuen Haugnes, Alexander Perez, Ola Engelsen, Ida H H Fosseide, Miguel J Castillejo, Trond Velde Bogsrud
{"title":"¹⁷⁷Lu-PSMA放射性配体疗法治疗转移性阉割耐药前列腺癌。","authors":"Rune Sundset, Hege Sagstuen Haugnes, Alexander Perez, Ola Engelsen, Ida H H Fosseide, Miguel J Castillejo, Trond Velde Bogsrud","doi":"10.4045/tidsskr.23.0478","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Treatment of castration-resistant metastatic prostate cancer with [¹⁷⁷Lu]PSMA radioligand.</p><p><strong>Case presentation: </strong>A man in his seventies with metastatic prostate cancer received castration therapy for four years, developing castration-resistant disease. PET/CT with [⁶⁸Ga]PSMA-11 showed high uptake in metastatic lymph nodes. The patient received 7.4 GBq [¹⁷⁷Lu]PSMA-I&T (Curium, Finland) as five treatments at five-week intervals. Five weeks after the first treatment, p-PSA dropped from 154 to 53 µg/L. Five weeks after the fifth treatment, p-PSA was 1.8 µg/L. [⁶⁸Ga]PSMA-11 PET/CT showed significant reduction in the size of metastases, with the largest decreasing in diameter from 10 to 4 mm. Seven months after the fifth treatment, p-PSA increased to 14.3 µg/L, and [⁶⁸Ga]PSMA-11 PET/ CT revealed additional skeletal metastases, while the lymph node metastases remained unchanged. Thus, the treatment had a good but temporary effect on the metastases.</p><p><strong>Interpretation: </strong>Treatment with [¹⁷⁷Lu]PSMA radioligand resulted in a temporary regression of the metastases.</p>","PeriodicalId":23123,"journal":{"name":"Tidsskrift for Den Norske Laegeforening","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"¹⁷⁷Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer.\",\"authors\":\"Rune Sundset, Hege Sagstuen Haugnes, Alexander Perez, Ola Engelsen, Ida H H Fosseide, Miguel J Castillejo, Trond Velde Bogsrud\",\"doi\":\"10.4045/tidsskr.23.0478\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Treatment of castration-resistant metastatic prostate cancer with [¹⁷⁷Lu]PSMA radioligand.</p><p><strong>Case presentation: </strong>A man in his seventies with metastatic prostate cancer received castration therapy for four years, developing castration-resistant disease. PET/CT with [⁶⁸Ga]PSMA-11 showed high uptake in metastatic lymph nodes. The patient received 7.4 GBq [¹⁷⁷Lu]PSMA-I&T (Curium, Finland) as five treatments at five-week intervals. Five weeks after the first treatment, p-PSA dropped from 154 to 53 µg/L. Five weeks after the fifth treatment, p-PSA was 1.8 µg/L. [⁶⁸Ga]PSMA-11 PET/CT showed significant reduction in the size of metastases, with the largest decreasing in diameter from 10 to 4 mm. Seven months after the fifth treatment, p-PSA increased to 14.3 µg/L, and [⁶⁸Ga]PSMA-11 PET/ CT revealed additional skeletal metastases, while the lymph node metastases remained unchanged. Thus, the treatment had a good but temporary effect on the metastases.</p><p><strong>Interpretation: </strong>Treatment with [¹⁷⁷Lu]PSMA radioligand resulted in a temporary regression of the metastases.</p>\",\"PeriodicalId\":23123,\"journal\":{\"name\":\"Tidsskrift for Den Norske Laegeforening\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2024-07-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Tidsskrift for Den Norske Laegeforening\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4045/tidsskr.23.0478\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/20 0:00:00\",\"PubModel\":\"Print\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tidsskrift for Den Norske Laegeforening","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4045/tidsskr.23.0478","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/20 0:00:00","PubModel":"Print","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:用[¹⁷⁷Lu]PSMA放射性配体治疗阉割耐药转移性前列腺癌:用[¹⁷⁷Lu]PSMA放射性配体治疗耐药转移性前列腺癌:一名七十多岁的转移性前列腺癌患者接受了四年的阉割治疗,出现了阉割抵抗性疾病。使用[⁶⁸Ga]PSMA-11 的 PET/CT 显示转移淋巴结的高摄取率。该患者接受了 7.4 GBq [¹⁷⁷Lu]PSMA-I&T (芬兰 Curium 公司)的治疗,共五次,每次间隔五周。第一次治疗五周后,p-PSA 从 154 微克/升降至 53 微克/升。第五次治疗五周后,p-PSA 为 1.8 µg/L。[⁶⁸Ga]PSMA-11 PET/CT 显示转移灶的大小显著缩小,最大的直径从 10 毫米缩小到 4 毫米。第五次治疗 7 个月后,p-PSA 升至 14.3 µg/L,[⁶⁸Ga]PSMA-11 PET/ CT 显示出更多的骨骼转移灶,而淋巴结转移灶保持不变。因此,治疗对转移灶有良好但暂时的效果:解读:使用[¹⁷⁷Lu]PSMA放射性配体治疗可使转移灶暂时消退。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
¹⁷⁷Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer.

Background: Treatment of castration-resistant metastatic prostate cancer with [¹⁷⁷Lu]PSMA radioligand.

Case presentation: A man in his seventies with metastatic prostate cancer received castration therapy for four years, developing castration-resistant disease. PET/CT with [⁶⁸Ga]PSMA-11 showed high uptake in metastatic lymph nodes. The patient received 7.4 GBq [¹⁷⁷Lu]PSMA-I&T (Curium, Finland) as five treatments at five-week intervals. Five weeks after the first treatment, p-PSA dropped from 154 to 53 µg/L. Five weeks after the fifth treatment, p-PSA was 1.8 µg/L. [⁶⁸Ga]PSMA-11 PET/CT showed significant reduction in the size of metastases, with the largest decreasing in diameter from 10 to 4 mm. Seven months after the fifth treatment, p-PSA increased to 14.3 µg/L, and [⁶⁸Ga]PSMA-11 PET/ CT revealed additional skeletal metastases, while the lymph node metastases remained unchanged. Thus, the treatment had a good but temporary effect on the metastases.

Interpretation: Treatment with [¹⁷⁷Lu]PSMA radioligand resulted in a temporary regression of the metastases.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Tidsskrift for Den Norske Laegeforening
Tidsskrift for Den Norske Laegeforening MEDICINE, GENERAL & INTERNAL-
CiteScore
0.60
自引率
18.20%
发文量
593
审稿时长
28 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信